NICE backs use of GlaxoSmithKline's asthma therapy Nucala after price cut

The National Institute for Health and Care Excellence issued draft guidance Thursday recommending NHS reimbursement of GlaxoSmithKline's Nucala (mepolizumab) for adults with severe asthma. The drug gained European approval last year as the first anti-IL-5 treatment for patients with severe refractory eosinophilic asthma.

NICE previously issued a negative ruling on Nucala noting that evidence provided by GlaxoSmithKline "did not reflect how it would be used in the NHS." The agency said Thursday that the company presented more information and reduced the price of the drug meaning it could be recommended as cost effective for the NHS. Patients receive Nucala by injection every four weeks, with a dose costing 840 pounds ($1062), before the NHS discount is applied.

For additional information on the asthma market, learn more at Targeted Therapies in Asthma.

NICE is also appraising Teva's similar therapy Cinqaero (reslizumab) for severe eosinophilic asthma. The agency indicated that after the first appraisal meeting, it asked the company to provide more information on the cost-effectiveness of the drug, which is marketed in the US as Cinqair. For related analysis, see Spotlight On Interview: An underdog story – Teva outlines commercial plans for Cinqair in increasingly competitive severe asthma space.

To read more Top Story articles, click here.